NEW YORK (GenomeWeb) – BG Medicine today reported third quarter revenues of $334,000, down 52 percent from $695,000 in the third quarter of 2014.

The decline was due to a drop in product revenues from sales of the company's BGM Galectin-3 test, which fell to $274,000 in the quarter, down 59 percent from $669,000 in Q3 2014. Product fee revenues were up 57 percent to $60,000 compared to $26,000 in the year-ago period.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that researchers in Italy are testing a gene drive aimed at controlling mosquito populations.

Researchers may experience the effects of the government shutdown for a while, the Los Angeles Times reports.

A new study finds that the majority of patients at a Tijuana clinic received a diagnosis after first-line genome sequencing, the San Diego Union-Tribune reports.

In Genome Biology this week: post-transcriptional modification-based stratification of glioblastoma, single-cell analysis of gene expression and methylation in human iPSCs, and more.